SUZ12
SUZ12 (Polycomb protein SUZ12) is a protein that switches other genes on and off. The public catalogues list it as an oncogene driver, a tumour suppressor and a fusion partner, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Leukaemia, Breast cancer, Prostate cancer and 4 more.
Overview
Polycomb group (PcG) protein. Component of the PRC2 complex, which methylates 'Lys-9' (H3K9me) and 'Lys-27' (H3K27me) of histone H3, leading to transcriptional repression of the affected target gene. The PRC2 complex may also serve as a recruiting platform for DNA methyltransferases, thereby linking two epigenetic repression systems.
Open Targets scores its association with cancer at 0.79 (direct and indirect evidence; datatypes affected pathway 0.72, literature 0.94, genetic association 0.02, somatic mutation 0.89, animal model 0.54). IntOGen calls it a driver in 4 cohorts (2 activating, 2 loss-of-function), covering Acute Myeloid Leukaemia, Prostate Adenocarcinoma, Sarcoma, NOS.
- Target · the protein and the cell it sits on
- Drug · antibody, small molecule, cell or radioligand
- Effect · signal, damage or kill
In plain words · SUZ12 (Polycomb protein SUZ12) is a protein that switches other genes on and off. The public catalogues list it as an oncogene driver, a tumour suppressor and a fusion partner, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Leukaemia, Breast cancer, Prostate cancer and 4 more.
- 1 · What it is
SUZ12 (Polycomb protein SUZ12) is a protein that switches other genes on and off. The public catalogues list it as an oncogene driver, a tumour suppressor and a fusion partner, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Leukaemia, Breast cancer, Prostate cancer and 4 more.
- 2 · What goes wrong in cancer
Polycomb group (PcG) protein. Component of the PRC2 complex, which methylates 'Lys-9' (H3K9me) and 'Lys-27' (H3K27me) of histone H3, leading to transcriptional repression of the affected target gene.
- 3 · How drugs use it
No product in this corpus aims at SUZ12 yet. Transcription factors have no pocket to plug, so drugs either degrade them or block the partner protein they need to dock on DNA.
External identifiers
Sources: HGNC HGNC:17101 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt Q15022 (protein name, function text, keywords and locations (REST API)); Open Targets ENSG00000178691 (association with cancer (MONDO_0004992) 0.79; per-cancer scores at or above 0.5: prostate cancer 0.51, sarcoma 0.53, non-Hodgkin lymphoma 0.52, skin cancer 0.52, breast cancer 0.61, leukaemia 0.61 (GraphQL API, CC0)); IntOGen SUZ12 (driver in 4 cohorts (Act 2, LoF 2); Compendium_Cancer_Genes.tsv release 20240920, CC0 1.0)
Biology
Polycomb group (PcG) protein. Component of the PRC2 complex, which methylates 'Lys-9' (H3K9me) and 'Lys-27' (H3K27me) of histone H3, leading to transcriptional repression of the affected target gene. The PRC2 complex may also serve as a recruiting platform for DNA methyltransferases, thereby linking two epigenetic repression systems. Genes repressed by the PRC2 complex include HOXC8, HOXA9, MYT1 and CDKN2A. Location: Nucleus (UniProt). Locus 17q11.2 (HGNC).
- Leukaemia: Open Targets association 0.61 with leukaemia (MONDO_0005059)
- Breast cancer: Open Targets association 0.61 with breast cancer (MONDO_0007254)
- Prostate cancer: Open Targets association 0.51 with prostate cancer (MONDO_0008315); IntOGen driver in 2 cohorts (PRAD)
- Sarcomas: Open Targets association 0.53 with sarcoma (MONDO_0005089); IntOGen driver in 1 cohort (SARCNOS)
- Non-Hodgkin lymphoma: Open Targets association 0.52 with non-Hodgkin lymphoma (MONDO_0018908)
- Skin cancer: Open Targets association 0.52 with skin cancer (MONDO_0002898)
Notes
top- Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: IntOGen calls it an activating (Act) driver in 2 cohorts; IntOGen calls it a loss-of-function (LoF) driver in 2 cohorts; UniProt disease notes describe a translocation or gene fusion involving the gene. Evidence tier "cohort-driver" is the strongest of those signals.
- Prevalence not recorded: none of the sources gives a positivity rate.
Latest papers
topQuery for this target: (TITLE:"SUZ12" OR ABSTRACT:"SUZ12" OR TITLE:"SUZ12 polycomb repressive complex 2 subunit" OR ABSTRACT:"SUZ12 polycomb repressive complex 2 subunit" OR TITLE:"Polycomb protein SUZ12" OR ABSTRACT:"Polycomb protein SUZ12" OR TITLE:"JJAZ1" OR ABSTRACT:"JJAZ1" OR TITLE:"KIAA0160" OR ABSTRACT:"KIAA0160" OR TITLE:"CHET9" OR ABSTRACT:"CHET9") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about SUZ12, not a curated reading list.
Similar pages
not linked directly; found by shared links- TargetEPS15
Shares Leukaemia (all types), Skin cancer (all types), Non-Hodgkin lymphoma (all types), Breast cancer (all types).
- TargetRUNX1T1
Shares Leukaemia (all types), Skin cancer (all types), Non-Hodgkin lymphoma (all types), Breast cancer (all types).
- TargetLEF1
Shares Leukaemia (all types), Skin cancer (all types), Non-Hodgkin lymphoma (all types), Breast cancer (all types).
- TargetZRSR2
Shares Leukaemia (all types), Skin cancer (all types), Non-Hodgkin lymphoma (all types), Acute myeloid leukaemia.
- TargetPOT1
Shares Leukaemia (all types), Skin cancer (all types), Non-Hodgkin lymphoma (all types), Sarcomas (soft tissue, bone, GIST).
- TargetPAX5
Shares Leukaemia (all types), Skin cancer (all types), Non-Hodgkin lymphoma (all types), Breast cancer (all types).
- TargetTRIM24
Shares Leukaemia (all types), Non-Hodgkin lymphoma (all types), Breast cancer (all types), IntOGen.
- TargetCNOT3
Shares Leukaemia (all types), Skin cancer (all types), Non-Hodgkin lymphoma (all types), IntOGen.